30 closest matches · ranked by relevance
Diabetes Mellitus, Type 2
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Hour 0 to Infinity (AUC0-∞) — 23.3; 24.9 µM*hr
Hepatic Insufficiency
Primary: Maximum Observed Plasma Concentration (Cmax) — 30.43; 26.96; 38.85 ng/mL
Human Immunodeficiency Virus (HIV) Infection
Primary: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Islatravir (ISL) in Plasma — 5.81; 7.74 Hours*μmol/Liter
Severe Hepatic Impairment · Healthy
Primary: Pharmacokinetic Parameters of MCI-186: Peak Drug Concentration (Cmax) — 347.6; 280.3 ng/mL
Hepatic Impairment · Healthy
Primary: Cmax — 538.1; 533.4; 429 ng/mL
Ovarian Neoplasms · Neoplasms · Solid Tumor
Primary: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Niraparib and Its Major Metabolite (M1) During…
Parkinson's Disease
Primary: Cmax - Maximum Plasma Concentration of BIA 9-1067 — 1108; 559 ng/mL
Hepatic Impairment
Primary: Maximum Plasma Concentration (Cmax) of PF-05221304 — 1220; 1591; 1433; 1592 Nanogram per milliliter (ng/mL)
Moderate Hepatic Impairment
Primary: Maximum Plasma Concentration (Cmax) of Pexidartinib Following a Single Dose in Participants With Moderate Hepatic Impairment Compared to Healthy Participants — 1420…
Type2 Diabetes Mellitus
Primary: Cmax (Maximum Observed Plasma Concentration) — 90.8; 96.5; 6.0; 6.6 ng/mL
Liver Diseases · Healthy
Primary: Area Under Curve From 0 to Infinity (AUC0-infinity) — 886; 552; 934; 956 ng*h/mL — p=0.1998
Healthy Volunteer
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Aleglitazar — 98.5; 113; 151 hours (h)*nanogram (ng)/milliliter (mL)
Hepatic Impairment
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-∞) of Plasma N-Hydroxycitidine (NHC) — 8930; 10900 hr*ng/mL
Hepatic Impairment
Primary: Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of LCZ696 Analytes (AHU377, LBQ657, and…
Moderate Hepatic Impairment
Primary: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Belzutifan — 22500; 14800 ng*hr/mL
Hepatitis C, Chronic
Primary: SVR12: Plasma HCV RNA Level Less Than 25 IU/mL at 12 Weeks After End of Treatment (EOT) — 61.1; 52.9 Percentage of participants
Gout
Primary: Maximum Observed Plasma Concentration (Cmax) — 25.6; 29.0; 38.2; 16.7 ng/mL
Hepatic Impairment
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MK-8189 — 5600; 4710 h*nmol/L
Hepatic Impairment
Primary: Pharmacokinetic Parameters of BAF312 and Selected Metabolites: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) — 68.3; 53.9; 73.7…
Type 2 Diabetes Mellitus · Hepatic Impairment
Primary: Area Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin — 1413; 1618 ng•hr/mL
Hepatic Insufficiency
Primary: AUC (0-inf) of Nintedanib — 200; 674; 92.7; 77.8 ng*h/mL
Insomnia · Hepatic Insufficiency
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to Infinity (0-∞) After Single Dose Suvorexant: Moderate Hepatic Insufficiency Participants…
Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of Total Alectinib — 107; 83.6; 85.5; 85.1 nanograms per milliliter (ng/mL)
Infection, Human Immunodeficiency Virus
Primary: Number of Events of ALT Elevation After Baseline, Controlling for APRI Score and Other Variables — 9; 4 events — p=0.02
Anaemia
Primary: Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of GSK1278863 and Its Metabolites — 296.2407…
Hepatic Impairment · Liver Diseases · Digestive System Diseases
Primary: AUC — 113.5; 114.6; 423.7; 1042 h*ng/mL
Hepatic Impairment
Primary: Cmax: Maximum Plasma Concentration of Lemborexant — 62.9; 48.7; 39.8 nanogram per milliliter (ng/mL)
Chronic Hepatic Impairment
Primary: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Time of the Last Quantifiable Concentration (AUC 0-t) of Preladenant After a Single Dose of…
Hepatic Insufficiency
Primary: Area Under the Concentration-time Curve of MK-0822 From Time 0 to Infinity (AUC0-∞) After Single Dose — 28.84; 33.79 μM*hr
Hepatic Impairment
Primary: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of M2951 — 186; 232; 362 hour*nanogram per milliliter (h*ng/mL)